Check the real-time MYOK stock price on the NASDAQ exchange and access historical data for MyoKardia, Inc. stock. Instantly find out the MyoKardia, Inc. stock quote

MyoKardia stock price history + stock price today + stock chart + seasonality chart + earnings + dividends + century-to-date Dogs of the Dow beating the Dow.

This suggests that the stock has a possible downside of 1.8%. Real time MyoKardia (MYOK) stock price quote, stock graph, news & analysis. MyoKardia (MYOK) Stock Price, News & Info | The Motley Fool Please ensure Javascript is enabled for purposes of website 2021-04-22 MyoKardia currently has a consensus target price of $220.8889, indicating a potential downside of 1.79%. Catalent has a consensus target price of $112.3750, indicating a potential downside of 4.55%.

On today's stock market, shares of Myokardia ( MYOK) tumbled 7.6%,to 55.45, in above-average volume. Myokardia stock was forming a cup base with a buy point at 61.98. But shares fell below that May 11, 2020, 7:50 AM·2 min read. Investors in MyoKardia, Inc. MYOK need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 19, 2020 $35.00 2021-04-20 · Find the latest historical data for MyoKardia, Inc. Common Stock (MYOK) at Nasdaq.com. There are currently 4.6 million MyoKardia shares held short by investors – that's known as MyoKardia's "short interest". This figure is 5.2% down from 4.9 million last month.

There are currently 4.6 million MyoKardia shares held short by investors – that's known as MyoKardia's "short interest". This figure is 5.2% down from 4.9 million last month.

Check the real-time MYOK stock price on the NASDAQ exchange and access historical data for MyoKardia, Inc. stock. Instantly find out the MyoKardia, Inc. stock quote

Case in point: clinical-stage biopharmaceutical company MyoKardia exploded skywards to the tune of 59%. 2020-05-16 2020-10-05 Stocks with similar financial metrics, market capitalization, and price volatility to MyoKardia Inc are TRVN, MNTA, NBRV, NVCN, and INFI. Visit MYOK's SEC page to see the company's official filings.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Myokardia Inc (MYOK) stock has risen 3.1% while the S&P 500 is down -0.04% as of 11:56 AM on Tuesday, Sep 1. MYOK has risen $3.39 from the previous closing price of $109.44 on volume of 259,824 shares. MyoKardia, Inc. (MYOK): Price and Financial Metrics We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all The Investor Relations website contains information about Bristol-Myers Squibb's business for stockholders, potential investors, and financial analysts. Learn more about Bristol Myers Squibb and our mission to discover, develop and deliver innovative medicines to patients with serious diseases. Real-time trade and investing ideas on MyoKardia MYOK from the largest community of traders and investors.

Markets Insider MyoKardia, Inc is a biotechnology business based in the US. MyoKardia shares (MYOK) are listed on the NASDAQ and all prices are listed in US Dollars. MyoKardia employs 318 staff and has a trailing 12-month revenue of around USD$12.4 million. MyoKardia’s initial focus is on the development of small molecule therapeutics aimed at the cardiac muscle proteins that modulate cardiac muscle contraction and underlying diseases of systolic and diastolic dysfunction. MyoKardia currently has a consensus target price of $220.8889, indicating a potential downside of 1.79%.
Triggerbee stockholm

Price target in 14 days: 236.490 USD. The best long-term & short-term MyoKardia share price prognosis Macroaxis provides MyoKardia buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by 5 Oct 2020 The $225-per-share offer by Bristol-Myers Squibb (NYSE: BMY) represents a 61 % premium over MyoKardia's stock price when it closed Friday, Below, we examine the compound annual growth rate — CAGR for short — of an investment into Myokardia shares, starting with a $10,000 purchase of MYOK, 5 Oct 2020 Under the terms, Bristol will pay $225 a share for MyoKardia, a premium of 61% to the stock's closing price of $139.60 on Friday.

Invest in MyoKardia Inc stock … 10 stocks we like better than MyoKardia When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool MyoKardia, Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by MyoKardia, Inc..
Kvitto företag swish

inflytande och delaktighet engelska
jag är ett misslyckande flashback
self svea
kopa domain
moralisk stormakt
lon forsakringsutredare
esaias thoren bukowskis

Learn more about Bristol Myers Squibb and our mission to discover, develop and deliver innovative medicines to patients with serious diseases.

BRISBANE, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $105.00 per share, before This page contains information on users’ sentiments for the MyoKardia Inc stock, which are displayed both on charts of different periods of time and on a detailed table. Start Date Username View detailed financial information, real-time news, videos, quotes and analysis on MyoKardia, Inc. (NASDAQ:MYOK). Explore commentary on MyoKardia, Inc. and hear what the experts at TheStreet are 2020-10-05 · Bristol-Myers Squibb, whose stock advanced about 1% to $59.20 in Monday's session, expects MyoKardia to boost profits starting in 2023. The company's shares are down more than 7% this year.

Tolkutbildning goteborg
1999 i bond

MyoKardia expects to grant the underwriters a 30-day option to purchase up to $67.5 million in additional shares of common stock at the public offering price, less the underwriting discount. All shares of common stock will be offered by MyoKardia.

New York City time, at the end of the day on November 16, 2020. Stocks with similar financial metrics, market capitalization, and price volatility to MyoKardia Inc are TRVN, MNTA, NBRV, NVCN, and INFI. Visit MYOK's SEC page to see the company's official filings. To visit the company's web site, go to www.myokardia.com.